Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Not listed
This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, based on safety and PK. The purpose of the Phase 2b, placebo-controlled portion is to evaluate the safety and efficacy of infigratinib in children \< 3 years old with ACH at the selected dose.
Diagnosis of ACH confirmed by genetic testing. If prospective participants had p... [+6]
Participants who have hypochondroplasia or diagnosis of genetic condition other... [+9]